Refine Search
(11)
(15)
(15)
(15)

Infectious Diseases

The total revenue from branded infectious diseases (ID) drugs and vaccines is projected to surpass $75bn. Bolstered by their growing human immunodeficiency virus (HIV) portfolios, Gilead Sciences and ViiV Healthcare – of which GlaxoSmithKline (GSK) owns a majority stake – were the leading players, together totaling almost $38bn in ID drug sales in 2017.

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline Review, H1 2018

  • $2,000
  • April 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline Review, H1 2018’, provides an overview of the Clostridium difficile Infections (Clostridium difficile Associated Disease) pipeline ...

Japanese Encephalitis - Pipeline Review, H1 2018

  • $2,000
  • April 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Japanese Encephalitis - Pipeline Review, H1 2018’, provides an overview of the Japanese Encephalitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ja...

Measles - Pipeline Review, H1 2018

  • $2,000
  • April 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Measles - Pipeline Review, H1 2018’, provides an overview of the Measles pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Measles, complete with analysi...

Hepatitis A - Pipeline Review, H1 2018

  • $2,000
  • April 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Hepatitis A - Pipeline Review, H1 2018’, provides an overview of the Hepatitis A pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hepatitis A, complete ...

Hepatitis C - Pipeline Review, H1 2018

  • $2,000
  • March 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Hepatitis C - Pipeline Review, H1 2018’, provides an overview of the Hepatitis C pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hepatitis C, complete ...

Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H1 2018

  • $2,000
  • March 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H1 2018’, provides an overview of the Influenza A Virus, H1N1 Subtype Infections pipeline landscape.

The report provides comprehensive information on...

Chlamydia Infections - Pipeline Review, H1 2018

  • $2,000
  • March 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Chlamydia Infections - Pipeline Review, H1 2018’, provides an overview of the Chlamydia Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chla...

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H1 2018

  • $2,000
  • March 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H1 2018’, provides an overview of the Ebolavirus Infections (Ebola Hemorrhagic Fever) pipeline landscape.

The report provides comprehensive info...

Genital Herpes - Pipeline Review, H1 2018

  • $2,000
  • February 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Genital Herpes - Pipeline Review, H1 2018’, provides an overview of the Genital Herpes pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Genital Herpes, ...

Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2018

  • $2,000
  • January 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2018’, provides an overview of the Hospital Acquired Pneumonia (HAP) pipeline landscape.

The report provides comprehensive information on the therapeutics ...

Sepsis - Pipeline Review, H1 2018

  • $2,000
  • January 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sepsis - Pipeline Review, H1 2018, provides an overview of the Sepsis (Infectious Disease) pipeline landscape.

Sepsis is an illness in which the body ...

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H2 2017

  • $2,500
  • December 2017
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H2 2017’, provides an overview of the Human Immunodeficiency Virus (HIV) Infections (AIDS) pipeline landscape.

The report provides comprehe...

Zika Virus Infections - Pipeline Review, H2 2017

  • $2,000
  • December 2017
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Zika Virus Infections - Pipeline Review, H2 2017’, provides an overview of the Zika Virus Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Zi...

Meningitis - Pipeline Review, H2 2017

  • $2,000
  • December 2017
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Meningitis - Pipeline Review, H2 2017’, provides an overview of the Meningitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Meningitis, complete wit...

Tuberculosis - Pipeline Review, H2 2017

  • $2,000
  • November 2017
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Tuberculosis - Pipeline Review, H2 2017’, provides an overview of the Tuberculosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Tuberculosis, comple...